Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa
Background Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and is currently the main induction treatment option for patients with locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy with standa...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2453091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592406385524736 |
|---|---|
| author | Kun-Peng Wu Qing-Qing Li Xu-Qiang Luo Xiao-Xi Wang Yan-Zhen Lai Dan Tian Hong-cheng Yang Xue-Ling Wei Lan-Ying Wang Qiu-Ming Li Dao Zhu Si-Jie Chen Yang-Si Li |
| author_facet | Kun-Peng Wu Qing-Qing Li Xu-Qiang Luo Xiao-Xi Wang Yan-Zhen Lai Dan Tian Hong-cheng Yang Xue-Ling Wei Lan-Ying Wang Qiu-Ming Li Dao Zhu Si-Jie Chen Yang-Si Li |
| author_sort | Kun-Peng Wu |
| collection | DOAJ |
| description | Background Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and is currently the main induction treatment option for patients with locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy with standard induction chemotherapy enhances its efficacy. This study aimed to evaluate the efficacy, toxicity, and survival outcomes of induction chemoimmunotherapy in patients with locoregionally advanced NPC.Methods This study analyzed 50 patients with stage IVa NPC between January 2020 and December 2023 in our hospital. Among them, 23 received induction chemoimmunotherapy, and 27 received induction chemotherapy. All patients underwent standard platinum-based concurrent intensity-modulated radiation therapy. We compared tumor response and toxicity during induction treatment and concurrent chemoradiotherapy (CCRT) between the two groups.Results The objective and complete response rates were significantly higher in the induction chemoimmunotherapy group compared to the induction chemotherapy group (95.7% vs 77.8%, and 39.1% vs 22.2%, respectively). All patients completed radical CCRT. Median follow-up was 24 months. Patients who received induction chemoimmunotherapy had longer event-free survival (EFS) compared to those who received induction chemotherapy (p = 0.029, Hazard Ratio and 95%confidence interval [CI]: 0.24 [0.07–0.85]). The 24-month EFS was higher in the induction chemoimmunotherapy group compared with the chemotherapy group (24-month EFS rates and 95%CI: 88.9% [95%CI: 68.3%–100%] vs 62.6% [95%CI: 43.1%–82.1%]). No significant differences in adverse events were observed between the two groups during induction treatment and CCRT.Conclusions Adding immunotherapy to induction chemotherapy may be an effective and safe choice for treating patients with stage IVa NPC. |
| format | Article |
| id | doaj-art-3e07eef495354a249c3fde91cfe06c83 |
| institution | Kabale University |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-3e07eef495354a249c3fde91cfe06c832025-01-21T08:35:14ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2025.2453091Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVaKun-Peng Wu0Qing-Qing Li1Xu-Qiang Luo2Xiao-Xi Wang3Yan-Zhen Lai4Dan Tian5Hong-cheng Yang6Xue-Ling Wei7Lan-Ying Wang8Qiu-Ming Li9Dao Zhu10Si-Jie Chen11Yang-Si Li12Department of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Otolaryngology-Head and Neck Surgery, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaDepartment of Oncology, Heyuan People’s Hospital, Guangdong Provincial People’s Hospital Heyuan Hospital, Heyuan, Guangdong, ChinaBackground Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and is currently the main induction treatment option for patients with locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy with standard induction chemotherapy enhances its efficacy. This study aimed to evaluate the efficacy, toxicity, and survival outcomes of induction chemoimmunotherapy in patients with locoregionally advanced NPC.Methods This study analyzed 50 patients with stage IVa NPC between January 2020 and December 2023 in our hospital. Among them, 23 received induction chemoimmunotherapy, and 27 received induction chemotherapy. All patients underwent standard platinum-based concurrent intensity-modulated radiation therapy. We compared tumor response and toxicity during induction treatment and concurrent chemoradiotherapy (CCRT) between the two groups.Results The objective and complete response rates were significantly higher in the induction chemoimmunotherapy group compared to the induction chemotherapy group (95.7% vs 77.8%, and 39.1% vs 22.2%, respectively). All patients completed radical CCRT. Median follow-up was 24 months. Patients who received induction chemoimmunotherapy had longer event-free survival (EFS) compared to those who received induction chemotherapy (p = 0.029, Hazard Ratio and 95%confidence interval [CI]: 0.24 [0.07–0.85]). The 24-month EFS was higher in the induction chemoimmunotherapy group compared with the chemotherapy group (24-month EFS rates and 95%CI: 88.9% [95%CI: 68.3%–100%] vs 62.6% [95%CI: 43.1%–82.1%]). No significant differences in adverse events were observed between the two groups during induction treatment and CCRT.Conclusions Adding immunotherapy to induction chemotherapy may be an effective and safe choice for treating patients with stage IVa NPC.https://www.tandfonline.com/doi/10.1080/07853890.2025.2453091Induction treatmentimmunotherapychemotherapychemoimmunotherapynasopharyngeal carcinoma |
| spellingShingle | Kun-Peng Wu Qing-Qing Li Xu-Qiang Luo Xiao-Xi Wang Yan-Zhen Lai Dan Tian Hong-cheng Yang Xue-Ling Wei Lan-Ying Wang Qiu-Ming Li Dao Zhu Si-Jie Chen Yang-Si Li Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa Annals of Medicine Induction treatment immunotherapy chemotherapy chemoimmunotherapy nasopharyngeal carcinoma |
| title | Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa |
| title_full | Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa |
| title_fullStr | Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa |
| title_full_unstemmed | Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa |
| title_short | Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa |
| title_sort | chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage iva |
| topic | Induction treatment immunotherapy chemotherapy chemoimmunotherapy nasopharyngeal carcinoma |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2025.2453091 |
| work_keys_str_mv | AT kunpengwu chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT qingqingli chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT xuqiangluo chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT xiaoxiwang chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT yanzhenlai chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT dantian chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT hongchengyang chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT xuelingwei chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT lanyingwang chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT qiumingli chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT daozhu chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT sijiechen chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva AT yangsili chemoimmunotherapyasinductiontreatmentinconcurrentchemoradiotherapyforpatientswithnasopharyngealcarcinomastageiva |